Oxagen Limited

Atopix Therapeutics Limited

Kudos Pharmaceuticals Limited

Maybridge Limited

Julia Vile

Graham Michael Wynne

Richard Edward Armer

Mark Whittaker

Eric Roy Pettipher

Niall Morrison Barr Martin

Graeme Cameron Murray Smith

Graeme Cameron Smith

Frank Schroer

Penny Jane Eversley

Charles Richard White

Roger Frank Newton

Diane Gillian Douglas

Colin Richard Dorgan

Carole Eliane Andree Maillol

Niall Morrison Martin

Compounds of general formula (II) wherein

Compounds having CRTH2 antagonist activity

Compounds of general formula (I) whereinW is chloro or fluoro;Ris phenyl optionally substituted with one or more substituents, selected from halo, &#x2014;CN, &#x2014;C-Calkyl, &#x2014;SOR, &#x2014;SOR, &#x2014;SON(R), &#x2014;N(R), &#x2014;NRC(O)R, &#x2014;COR, &#x2014;CONRR, &#x2014;NO, &#x2014;OR, &#x2014;SR, &#x2014;O(CH)OR, or &#x2014;O(CH)O(CH)ORwherein

Compounds of general formula (II) whereinW is chloro or fluoro;Ris phenyl optionally substituted with one or more substituents, selected from halo, &#x2014;CN, &#x2014;C-Calkyl, &#x2014;SOR, &#x2014;SOR, &#x2014;SON(R), &#x2014;N(R), &#x2014;NRC(O)R, &#x2014;COR, &#x2014;CONRR, &#x2014;NO, &#x2014;OR, &#x2014;SR, &#x2014;O(CH)OR, or &#x2014;O(CH)O(CH)ORwherein

A method of treatment of a disease of the human or animal body mediated by PARP comprising administering to such a subject a therapeutically effective amount of a compound of formula: or an isomer, salt, solvate, chemically protected form, and prodrug thereof, wherein:

Phthalazinone derivatives

Growing community of inventors

Oxon, United Kingdom

Julia Vile